menu
    • menu
    [{"orgOrder":0,"company":"Veristat","sponsor":"Laboratorios HIPRA","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Protein COVID-19 Vaccine Recombinant","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Veristat","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Veristat \/ Veristat","highestDevelopmentStatusID":"15","companyTruncated":"Veristat \/ Veristat"},{"orgOrder":0,"company":"Veristat","sponsor":"Antibe Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Veristat","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Veristat \/ Veristat","highestDevelopmentStatusID":"8","companyTruncated":"Veristat \/ Veristat"},{"orgOrder":0,"company":"Veristat","sponsor":"Dicerna Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Nedosiran","moa":"L-lactate dehydrogenase A chain mRNA","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Veristat","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Veristat \/ Veristat","highestDevelopmentStatusID":"10","companyTruncated":"Veristat \/ Veristat"},{"orgOrder":0,"company":"Veristat","sponsor":"Larimar Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Veristat","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Veristat \/ Veristat","highestDevelopmentStatusID":"8","companyTruncated":"Veristat \/ Veristat"},{"orgOrder":0,"company":"Veristat","sponsor":"Larimar Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Veristat","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Veristat \/ Veristat","highestDevelopmentStatusID":"8","companyTruncated":"Veristat \/ Veristat"},{"orgOrder":0,"company":"Veristat","sponsor":"Larimar Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Veristat","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Veristat \/ Veristat","highestDevelopmentStatusID":"8","companyTruncated":"Veristat \/ Veristat"},{"orgOrder":0,"company":"Veristat","sponsor":"CanariaBio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Oregovomab","moa":"Mucin-16","graph1":"Oncology","graph2":"Phase III","graph3":"Veristat","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Veristat \/ Veristat","highestDevelopmentStatusID":"10","companyTruncated":"Veristat \/ Veristat"},{"orgOrder":0,"company":"Veristat","sponsor":"Veristat","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"G001","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Veristat","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Veristat \/ Veristat","highestDevelopmentStatusID":"8","companyTruncated":"Veristat \/ Veristat"},{"orgOrder":0,"company":"Veristat","sponsor":"PreveCeutical Medical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Agreement","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Veristat","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Gel","sponsorNew":"Veristat \/ PreveCeutical Medical","highestDevelopmentStatusID":"4","companyTruncated":"Veristat \/ PreveCeutical Medical"}]

    Find Clinical Drug Pipeline Developments & Deals by Veristat

    Menu

    Veristat

    EVENTS

    • Webinars & Exhibitions

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Veristat

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed

                            Veristat

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Protein COVID-19 Vaccine Recombinant

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Recipient : Laboratorios HIPRA

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Veristat Congratulates HIPRA for EMA Approval of Its BIMERVAX® COVID-19 Vaccine

                            Details : Bimervax is a recombinant protein vaccine whose active substance is SARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer – B.1.351-B.1.1.7 strains, it provides immune response at humoral and cellular level, ag...

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            April 25, 2023

                            Lead Product(s) : Protein COVID-19 Vaccine Recombinant

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Recipient : Laboratorios HIPRA

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Veristat

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed

                            Veristat

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oregovomab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : CanariaBio

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive R...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            April 20, 2022

                            Lead Product(s) : Oregovomab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : CanariaBio

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Veristat

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed

                            Veristat

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nomlabofusp

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Recipient : Larimar Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Larimar Therapeutics Provides Update on CTI-1601 Clinical Program

                            Details : CTI-1601 is a recombinant fusion protein intended to deliver human frataxin into the mitochondria of patients with Friedreich’s ataxia who are unable to produce enough of this essential protein.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            February 14, 2022

                            Lead Product(s) : Nomlabofusp

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Recipient : Larimar Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Veristat

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed

                            Veristat

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nomlabofusp

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Recipient : Larimar Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Larimar Reports Positive Topline Phase 1 Data Showing Dose-Dependent Increases in Frataxin Levels in Patients ...

                            Details : Data show that repeated subcutaneous administration of CTI-1601 resulted in dose-dependent increases in frataxin (FXN) levels from baseline compared to placebo controls.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            November 05, 2021

                            Lead Product(s) : Nomlabofusp

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Recipient : Larimar Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Veristat

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed

                            Veristat

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : G001

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase II

                            Recipient : BUZZZ Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of G001 in Patients With Osteoarthritis (OA) of the Knee

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            August 16, 2021

                            Lead Product(s) : G001

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase II

                            Recipient : BUZZZ Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Veristat

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed

                            Veristat

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nomlabofusp

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Recipient : Larimar Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Larimar Therapeutics Reports FDA Clinical Hold on CTI-1601 and Termination of Recently Announced Private Place...

                            Details : CTI-1601 is a recombinant fusion protein intended to deliver human frataxin into the mitochondria of patients with FA who are unable to produce enough of this essential protein.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            May 25, 2021

                            Lead Product(s) : Nomlabofusp

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Recipient : Larimar Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Veristat

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed

                            Veristat

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nedosiran

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase III

                            Recipient : Dicerna Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dicerna Reports Positive Top-Line Results From PHYOX™2 Pivotal Clinical Trial of Nedosiran for the Treatment...

                            Details : Nedosiran achieved the primary endpoint in the PHYOX2 trial, demonstrating a statistically significant reduction from baseline in urinary oxalate (Uox) excretion compared to placebo (p<0.0001).

                            Product Name : DCR-PHXC

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            May 08, 2021

                            Lead Product(s) : Nedosiran

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase III

                            Recipient : Dicerna Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Veristat

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed

                            Veristat

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Otenaproxesul

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase II

                            Recipient : Antibe Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Antibe Therapeutics Receives FDA Clearance of IND Application for Otenaproxesul for Osteoarthritis Pain

                            Details : Antibe’s lead drug, otenaproxesul, is entering Phase III for the treatment of osteoarthritis pain. Additional assets under development include a safer alternative to opioids for peri-operative pain, and a GI-protective alternative to low-dose aspirin.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 29, 2021

                            Lead Product(s) : Otenaproxesul

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase II

                            Recipient : Antibe Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Veristat

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed

                            Veristat

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : PreveCeutical Medical

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            PreveCeutical Prepares for Clinical Trials for its Sol-Gel COVID-19 Program

                            Details : Under the terms of the consulting agreement, Veristat will provide services to design and develop PreveCeutical COVID-19 Sol-Gel clinical program and write the required protocol.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            April 08, 2020

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : PreveCeutical Medical

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Veristat

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed

                            Veristat

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Otenaproxesul

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase II

                            Recipient : Antibe Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of ATB-346 Versus Placebo in Osteoarthritis Patients

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 07, 2019

                            Lead Product(s) : Otenaproxesul

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase II

                            Recipient : Antibe Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth